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ABSTRACT
In some clinical studies performed in patients with
perennial allergic rhinitis, ramatroban, a new throm-
boxane A2 receptor antagonist, significantly improved
nasal symptoms. As yet the mechanism of action of this
drug has not been fully elucidated. In the present study
we investigated the effects of ramatroban on changes
in nasal reactivity and levels of inflammatory cells and
mediators in nasal lavage fluid after allergen
challenge. Ramatroban was administered orally at a
daily dose of 150 mg (b.i.d.) for 4 weeks to 11 patients
with perennial allergic rhinitis exhibiting positive
responses to nasal allergen challenge with house dust
mite. Analysis of variance revealed that there was a
significant decrease in eosinophil counts and eosino-
phil cationic protein levels in nasal lavage fluid when
compared with values immediately before allergen
challenge before and after ramatroban treatment.
Histamine, tryptase and albumin levels were signifi-
cantly decreased in analysis of variance before and
after ramatroban treatment. The degree of nasal
reactivity to histamine was also significantly decreased
after the ramatroban treatment. These findings indicate
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that ramatroban decreases important pathogenic
factors in allergic rhinitis, resulting in an improvement
in nasal symptoms.
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INTRODUCTION
Recent research has indicated that various mediators may
participate in the pathogenesis of allergic rhinitis in addi-
tion to histamine, which is known to play an important
role. These include leukotrienes (LT) and other inflam-
matory mediators, such as prostaglandins (PG), throm-
boxane A2 (TXA2) and platelet-activating factor (PAF).
Prostaglandin D2 (PGD2) causes swelling of the nasal
rnucosc.' Thromboxane A2 causes constriction of lower
airway smooth muscle and increases vascular perme-
ability and airway hvperreoctivitv.?" In the nasal mucosa,
where smooth muscle is localized in blood vessels, TXA2
probably plays an important role in the aggravation of
nasal allergic symptoms by increasing vascular perme-
ability and airway hyperreactivity.
Ramatroban (BAY u 3405)5 is a TXA2 receptor
antagonist synthesized by Bayer AG (Wuppertal,
Germany). Ramatroban has been reported to inhibit
allergen-induced increases in vascular permeability in the
nasal mucosa, an elevation of nasal airway resistance
and eosinophil infiltration in the nasal mucosa in the
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experimental rhinitis model of sensitized guinea piqs.? In
some clinical studies performed in patients with perennial
allergic rhinitis, ramatroban significantly improved nasal
symptoms, including nasal obstruction." As yet the
mechanism of action of this drug has not been fully
elucidated.
In the present study we investigated the effects of
ramatroban on changes in nasal reactivity and levels of
inflammatory cells and mediators in nasal lavage fluid
after allergen challenge in patients with perennial allergic
rhinitis and discussed how TXA2 is involved in the
pathogenesis of allergic rhinitis.
METHODS
Subjects
The present study was performed in patients with peren-
nial allergic rhinitis who exhibited positive responses to
nasal allergen challenge with house dust mite and
positive responses to an intracutaneous reactivity test
(or RAST/MAST/CAP) or positive detection of
eosinophils in nasal secretions. Eleven patients (10
male and one female), ranging in age from 18 to 36
years (mean (± SD) 27.2 ± 6.4 years) participated in
the study. During a 1 week run-in period, nasal
symptoms were evaluated, using Okuda's enteric." as
severe for two patients, moderate for eight patients and
mild for one patient. Two patients who skipped the
scheduled visit for nasal allergen challenge testing 4
weeks after treatment were excluded from analysis for
nasal allergen challenge. One patient whose nasal
symptoms were evaluated as mild in the run-in period
was excluded from analysis for clinical efficacy of nasal
symptoms.
The present study was performed from October 1995
to December 1995 with the approval of the Institutional
Review Board of Chiba University School of Medicine
Affiliated Hospital and in compliance with Japan's Good
Clinical Practice (GCP).
Prior to the study, written informed consent to
participate in the study was obtained individually from
patients after provision of detailed information about the
test drug, contents of the study and subjects' human
rights.
Study schedule
After a 1 week run-in period, a ramatroban 75 mg tablet
was administered twice daily, after breakfast and before
bedtime, for 4 weeks. Patients were subjected to nasal
allergen challenge on the first day (before the first dose)
and the last day (day 29; after the last dose) of treatment.
Nasal lavage was performed 15 min and immediately
before allergen challenge and then 10 and 30 min and
1 h after allergen challenge. In addition, nasal reactivity
to histamine was examined 2 h after allergen challenge
(Fig. 1).
Nasal allergen challenge
After a patient blew his/her nose at rest, two house-dust
allergen discs (Allergen Disc®; Torii Pharmaceutical Co.
Ltd, Tokyo, Japan) were placed on the anterior end of the
right and left inferior conchal mucosa for 10 min to
induce nasal mucosal reactivity.
Nasal lavage
With a patient bent forward at the head in a sitting
position, a nozzle, connected to a syringe by a tube, was
inserted into a nostril to close the opening tightly and the
nasal cavity was washed with 20 mL physiological saline
warmed at 3rC. The syringe was then inserted into the
other nostril and the same process was repeated,








Fig. 1 The study schedule. Nasal
allergen (house dust) challenge and
nasal lavage were performed at 15
and 0 min before and then 10, 30
and 60 min after allergen challenge,
and nasal reactivity to histamine was
examined at 2 h after allergen chal-
lenge before and after 4 weeks treat-
ment with ramatroban (150 mg/day)
The last tablet of ramatroban was administered 2 h before nasal allergen challenge.
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each side. lavage fluid recovered was measured, mixed
thoroughly, filtered through a nylon filter net (Nippon
Rikagaku Kikai Co., Tokyo, Japan) to remove mucin and
then centrifuged for 20 min at 4°C at 400 g. The
supernatant was stored frozen at -80°C until assayed for
chemical mediator levels. The sediment was subjected to
inflammatory cell count measurement.
levels of mediators in nasal lavage fluid were measured
by a third party, blinded to the purpose and details of the
study (Mitsubishi Kagaku Bio-Clinical laboratories Inc.,
Tokyo, Japan). Eosinophil cationic protein (ECP),
histamine, tryptase and albumin were assayed using a
Pharmacia ECP radioimmunoassay (RIA) kit (Pharmacia,
Uppsala, Sweden), a Histamine CT EIKEN kit (Eiken
Chemical, Tokyo, Japan), a Pharmacia Tryptase RIA CT®
(Pharmacia) and a Superior Microalbumin kit (Japan
DPC, Tokyo, Japan), respectively.
Cell counts were performed separately by two
scientists. Eosinophils were counted by a hemato-
cytometer after staining cells with Hinkelman's stain.
Mean values of the counts obtained by two scientists were
used for data analysis.
Nasal reactivity to histamine
Physiological saline solution and 0.001, 0.01, 0.1, 0.25,
0.5 and 1% concentrations of histamine hydrochloride
were prepared. Using a micropipette, physiological
saline and the histamine solutions were infused, at a vol-
ume of 20 III each, near the anterior end of the median
plane of the right and left inferior conchae with increasing
concentrations of histamine hydrochloride. Nasal pro-
vocation by histamine titration was continued for all
patients up to 0.25% histamine. Furthermore, nasal
provocation was continued in patients in whom sneezing
had not been evoked once or more and/or in whom the
amount of nasal secretion produced had not exceeded
0.5 g or more, until these symptoms were attained. The
number of sneezes and the weight of nasal secretions
were measured during 10 min following application of
each dilution. Nasal secretion was collected as follows:
the secretion was wiped off with tissue paper of a known
weight during 10 min. Then, a patient was asked to blow
his or her nose with the tissue paper after 10 min and the
weight of the nasal secretion collected in the tissue was
measured.
Nasal reactivities to histamine before and after
ramatroban treatment were evaluated using the
following three parameters: (i) the threshold histamine
concentration to induce one or more sneezes and to
produce 0.5 g or more nasal secretion; (ii) the sum of
the number of sneezes and the amount of nasal
secretion induced by 0.001-0.25% histamine solution;
and (iii) the degree of nasal reactivity, determined as a
combination of the number of sneezes and the amount
of nasal secretion induced by 0.001-0.25% histamine
dilution, using the six grades shown in Table 1.
Clinical symptoms
Patients were given allergy diaries to record nasal symp-
toms during the study period. Scores for nasal symptoms
were evaluated using Okuda's evaluation criteric," with a
four grade scale of 3+,2+, + and -, at each scheduled
visit. General clinical laboratory findings (hematology,
biochemical profile and urinalysis) were examined before
and after ramatroban treatment, together with results
of investigation of subjective and objective adverse
reactions.
Statistical analyses
The following analysis was made for cell counts and
mediator levels by converting measured values to log-
arithms, as a study of the variance of measured values
Table 1. Criteria for the degree of nasal reactivity, obtained by combining the number of sneezes and the amount of nasal
secretion induced by 0.001, 0.01, 0.1 and 0.25% histamine solution
--------------
Degree of nasal reactivity
+ 2+ 3+ 4+ 5+
----
No. sneezes* 0 1-2 3-6 7-10 11-15 :::;16
Amount of nasal
secretion (g)t :::;0.7 0.8-1.0 1.1-3.0 3.1-6.0 6.1-10.0 s 10.1
When the degree determined for sneezing differed from that determined for nasal secretion, the higher degree was chosen and reduced by one
grade.
*Sum of the number of sneezes induced by 0.001, 0.01, 0.1 and 0.25% histamine solution; tsum of the amount of nasal secretion induced by
0.001,0.01,0.1 and 0.25% histamine solution.
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implied that any of them were close to log-normal
distribution rather than normal distribution. Changes
after allergen challenge against values immediately
before allergen challenge were determined by the
Wilcoxon signed rank test before ramatroban treatment
and at 4 weeks after ramatroban treatment. Different
logarithmic values and logarithmic change rates [In
(value after challenge/value immediately before
challenge)] before and after ramatroban treatment were
compared using an analysis of variance for repeated
measures (ANOYA). When significant differences were
noted, comparisons were made at every time point with
the Wilcoxon signed rank test.
The Wilcoxon signed rank test was also used for com-
parison of nasal mucosal reactivity and nasal symptoms
between before and after ramatroban treatment.
P < 0.05 was considered statistically significant.
Measured values are expressed as the mean ± SEM and
cell counts and mediator levels are expressed as the
geometric mean (± geometric standard error). Statistical
analysis was made with the statistical software package
SAS (SAS Institute Inc., Cary, NC, USA).
gen challenge after ramatroban administration in com-
parison with before administration (Fig. 2).
Mediator levels in nasal lavage fluid
Eosinophil cationic protein
Before treatment, ECP levels in nasal lavage fluid were
significantly increased at 10 (P = 0.0039), 30
(P = 0.0313) and 60 min (P = 0.0313) after challenge.
However, after ramatroban treatment, a significant
increase in ECP levels was noted only 10 min after
challenge (P = 0.0391).
There were significant differences noted in logarithmic
change rates between before and after ramatroban
treatment by ANOYA (P = 0.0118). The logarithmic
change rates tended to decrease before and after
ramatroban treatment at 10 min after allergen challenge
(P = 0.0742). Comparison by logarithm before and after
administration exhibited significant differences at 10 min
after allergen challenge (P = 0.0195; Fig. 3a).
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Fig. 2 Effect of ramatroban on the infiltration of eosinophils
in nasal lavage fluid after nasal allergen challenge. Eosinophil
counts were measured before (0) and after (.) 4 weeks
ramatroban treatment. Values are the mean ± SEM of
logarithmic change rate from values before challenge [In (after
challenge/before challenge)] in nine patients. *P < 0.05, **P
< 0.0 1 compared with before challenge (0 min). r*--,


























Changes in eosinophil counts in nasal lavage
fluid
Before ramatroban treatment, eosinophil counts in nasal
lavage fluid were 143 ± 1.55 and 116 ± 1.40 /mL 15
min before and immediately before nasal allergen
challenge, respectively; the counts were significantly
increased 30 and 60 min after challenge, being 189 ±
1.46, 536 ± 1.57 (P = 0.0039) and 803 ± 1.51 /mL
(P = 0.0039) at 10, 30 and 60 min after challenge,
respectively. After 4 weeks ramatroban treatment, the
eosinophil counts in nasal lavage fluid were 236 ± 1.40
and 204 ± 1.29 /mL 15 min before and immediately
before nasal allergen challenge, respectively. After
challenge, a significant increase was noted only at 60
min after challenge, with counts of 323 ± 1.45, 234 ±
1.44 and 472 ± 1.24 /mL (P = 0.0195) at 10, 30 and
60 min after challenge, respectively.
Analysis of variance showed significant differences in
logarithmic change rates of eosinophil cell counts
between before and after ramatroban treatment (P =
0.0382; ANOYA). Logarithmic change rates against
values immediately before allergen challenge exhibited a
significant decrease (P = 0.0391) at 30 min after aller-
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Fig. 3 Effect of ramatroban on chemical mediators in nasal lavage fluid after nasal allergen challenge. (a) Eosinophil cationic
protein (b) histamine, (c) tryptase and (d) albumin were measured before (--0--) and after (--e--) 4 weeks ramatroban treatment.
Values are the geometric mean ± geometric SEM in nine patients. *P < 0.05, **P < 0.01 compared with values for 0 min before
challenge. } P < 0.05, ~* P < 0.01 compared with corresponding values before and after ramatroban treatment.
Histamine Tryptase
Before ramatroban treatment, histamine levels in
nasal lavage fluid were quite high, even 15 min
before nasal allergen challenge. Although they
decreased immediately before challenge due to the
first nasal washing performed 15 min previously, they
were significantly increased 10 min after challenge
(P = 0.0391; Fig. 3b). Four weeks after ramatroban
treatment, no significant increases were noted in
histamine levels at any time point after allergen
challenge.
Comparison of logarithms before and after
ramatroban treatment exhibited significant differences by
ANOYA (P = 0.0026). Histamine levels were significantly
lower after ramatroban treatment at 15 min before
challenge (P = 0.0273) and 10 (P = 0.0117), 30 (P =
0.011 7) and 60 min (P = 0.0273) after challenge.
After allergen challenge, tryptase levels in nasal lavage
fluid were somewhat, but not significantly, increased at all
monitoring points both before and after ramatroban
treatment.
Comparison of logarithms before and after rama-
troban treatment exhibited significant differences by
ANOYA (P = 0.0003). Tryptase levels were significantly
lower after ramatroban treatment at 15 min before
challenge, immediately before challenge and 30 and 60
min after challenge (P = 0.0195, 0.0039, 0.0391 and
0.0234, respectively; Fig. 3c).
Albumin
After allergen challenge, albumin levels in nasal
lavage fluid were significantly increased (P < 0.05) at
Correlation between ECP levels and nasal
reactivity to histamine
Peak logarithmic ECP levels and degrees of nasal
reactivity to histamine determined before and after
ramatroban treatment were plotted to investigate their
correlation. As shown in Fig. 6, a high correlation
(r = 0.8085; P = 0.0001; Spearman's rank order
correlation) was observed between ECP levels and the
degree of nasal reactivity.
all time points tested, both before and after rama-
troban treatment.
There was a tendency towards a decrease in logarithmic
change rates before and after ramatroban treatment by
ANOVA (P = 0.0688). The logarithmic change rates were
significantly lower after ramatroban treatment at 30 min (P
= 0.0391) after allergen challenge. Significant differences
were noted in logarithms before and after ramatroban
treatment by ANOVA (P = 0.0333), particularaly at 30 min
after allergen challenge (P = 0.0273; Fig. 3d).
Nasal reactivity to histamine
Threshold concentrations of histamine [median (25-75%
intervals)] were shifted from 0.01% (0.01-0.25%) before
treatment to 0.1 % (0.01-1 %) after treatment in terms of
sneezing, and from 0.1 % (0.01-0.1 %) to 0.1 %
(0.1-0.5%) in terms of nasal secretion, which tended to
increase, although not significantly, after ramatroban
treatment (P = 0.0625 for sneezing; P = 0.0938 for
nasal secretion). The mean number of sneezes induced
by local application of 0.25% histamine was decreased
from 2.33 ± 0.76 times before treatment to 1.44 ±
0.65 times after ramatroban treatment; however, this
decrease was not significant. In contrast, the mean
amount of nasal secretion was significantly decreased
(P = 0.0039) after ramatroban treatment, with values of
1.98 ± 0.36 and 0.96 ± 0.27 g before and after
ramatroban treatment, respectively (Fig. 4). The degree
of nasal mucosal reactivity to histamine was significantly
decreased (P = 0.0156) after ramatroban treatment
(Fig. 5).
o 4




















































Fig. 4 Effect of ramatroban on nasal hyperractivity to
histamine. The number of sneezes (a) and the amount of nasal
secretions (b) were measured for 10 min after 0.25% histamine
solution challenge before and after 4 weeks ramatroban
treatment in nine patients. Values are individual values and are
also given as the mean ± SE (j). **P < 0.01 between before
and after ramatroban treatment. NS, not significant (P ~ 0.1).
Clinical symptoms
Clinical efficacy was determined for 10 of 11 patients
participating in the study, excluding one patient whose
nasal symptoms were evaluated as mild in the run-in
period. Scores for nasal obstruction were significantly
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Fig. 5 Changes in the degree of nasal reactivity to histamine
before and after 4 week ramatroban treatment in nine patients.
The degree of nasal reactivity was judged on the basis of both
the sum of the numbers of sneezes and the sum of the amount
of nasal secretions induced by 0.001, 0.01, 0.1 and 0.25%
histamine solution using the criteria shown in Table 1.
*P < 0.05 between before and after ramatroban treatment.

















decreased from (mean ± SD) 1.8 ± 0.4 points before
treatment to 0.9 ± 0.6 points after the 4 week rama-
troban treatment (P = 0.0078).
Adverse reactions
No subjective/objective adverse reactions or abnormal
changes in laboratory test results were observed.
DISCUSSION
Thromboxane A2 and its receptors take part in the
pathogenesis of allergic disorders via complex mecha-
nisms involving other inflammatory mediators. For
example, leukotriene (LT)C4 and LTD4 induce broncho-
constriction via cyclo-oxgenase products, including
TXA29 11 and platelet-activating factor (PAF)-induced
airway reactivity is inhibited by OKY 046, a TXA2 synthe-
tase inhibitor.'? Prostaglandin (PG)D2 and PGF2a induce
airway constriction by binding to TXA2 receptors.P'!" In
addition, ramatroban, a TXA2 receptor antagonist, has
been shown to inhibit bronchoconstriction induced by the
TXA2 analog U46619, PGD2 and PGF2a and even that by
the allergens LTC4 and LTD4 . 17 These findings indicate
that blockade of TXA2 receptor function by ramatroban
can reduce levels of various mediators, such as LTC4,
LTD4, PAF and PGD2, which cause swelling of the nasal
mucosa. In fact, ramatroban has been shown to improve
various pathophysiological conditions in an experimental
model of allergic rhinitis" and clinical findings in patients
with perennial allergic rhinitis have confirmed the efficacy
of rornotrobcn.?
In the present study, inflammatory mediator levels and
eosinophil counts in nasal lavage fluid after allergen
challenge were compared before and after treatment
with ramatroban in patients with perennial allergic
rhinitis. The effect of a TXA2 receptor antagonist on nasal
reactivity to histamine was also examined.
As shown in the present study, 4 week ramatroban
treatment significantly inhibited the increase in eosinophil
counts in nasal lavage fluid 30 min after allergen
challenge. It also reduced ECP levels after challenge.
However, it has not been reported whether or not TXA2
itself possesses an effect on eosinophil chemotaxis. It is
unclear how ramatroban reduces allergen-induced
eosinophil infiltration and ECP levels in the nasal mucosa.
Its possible mechanisms of action include the following:
1. It has been observed that ramatroban inhibits the
release of RANTES (regulated on activation normal T
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expressed and secreted chemokine) induced by U46619
from human blood (S Sawada, pers. comm., 1996). It is
known that RANTES promotes adhesion of eosinophils to
vascular endothelial cells, increases the passage of
eosinophils through vascular endothelial intercellular
spaces and also has an eosinophil chemotactic effect. 18
Inhibition of eosinophil chemotaxis to nasal mucosa
observed in the present study was possibly a result of
inhibition of RANTES by ramatroban.
2. Eosinophils are considered to undergo chemotaxis from
microvascular vessels to the nasal mucous membrane
proper, while increased vascular permeability appears to
promote eosinophil chemotaxis in the presence of
eosinophil chemotactic factors. Ramatroban inhibits
increases in vascular permeability, as confirmed in the
present study by the finding that it significantly inhibited
allergen-induced increases in albumin levels in nasal
lavage fluid, resulting in inhibition of eosinophil infiltration.
The degree of nasal reactivity to histamine was
significantly decreased after 4 weeks ramatroban
treatment, with a tendency towards a decrease in the
number of histamine-induced sneezes and a significant
decrease in the amount of histamine-induced nasal
secretion. These findings confirmed that ramatroban
attenuates non-specific nasal hyperreactivity. The
mechanism responsible for the reduction in nasal
hyperreactivity includes the following possibilities:
1. We have previously reported a good correlation
between ECP levels and nasal reoctivity." Inhibition of
nasal reactivity by ramatroban may result from decreased
ECP levels, because a high correlation was found
between the degree of nasal reactivity and ECP levels.
2. It has been suggested that TXA2 may act directly on
histamine receptors in mucosal epithelial cells and
vascular endothelial cells in the nasal cavity. Takehana et
al. reported that inhalation of a TXA2 analog (STA2)
resulted in increased reactivity to histamine in guinea
pigs, with increases in the number of histamine receptors
and muscarinic receptors in the lung. 12 A previous study
showed that the expression of mRNA of the histamine H 1
receptor was up-regulated in epithelial cells isolated from
human nasal mucosa following pretreatment with the
TXA2 analog U46619 for 6 h.20 These reports suggest
that the inhibition of nasal reactivity to histamine may
result from suppression of up-regulation of histamine
receptors by ramatroban.
3. The following findings suggest that ramatroban may
inhibit acetylcholine release from Vidian nerves and
suppress nasal reactivity. Thromboxane A2 is known to
promote airway hvperreoctivitvv' Thromboxane A2
synthetase inhibitors and TXA2 receptor antagonists,
including ramatroban, have been reported to suppress
bronchial hyperreactivity in asthmatics. 21- 23 Chung et al.
have attributed airway hyperreactivity induced by TXA2 to
its promotion of acetylcholine release from nerve
terminols."
In the present study, ramatroban treatment decreased
levels of the basophil cell-derived mediators histamine
and tryptase. Levels of histamine and tryptase in nasal
lavage fluid were significantly lower after treatment than
before treatment, even before allergen challenge. Our
findings indicate that not only allergen-induced but also
spontaneous secretion of these mediators was inhibited
by ramatroban treatment. Proliferation of mast cells is
known to be enhanced by T cell-derived cytokines, such
as interleukin-3, -4, -9 and _10.25,26 It has also been
reported that ramatroban inhibits lymphocyte infiltra-
tion.:" The present study suggests that decreases in
tryptase levels in nasal lavage fluid resulted from a
decrease in the numbers of activated mast cells due to a
decrease in lymphocyte infiltration into inflammatory
tissue. It has been recently reported that RANTES also
causes chemotaxis of mast cells. 28 Decreases in his-
tamine and tryptase levels may result from decreases in
numbers of mast cells due to the inhibition of production
and release of RANTES, as they also result from
decreases in eosinophil counts.
In conclusion, ramatroban, a TXA2 receptor antagon-
ist, attenuated non-specific nasal hyperreactivity and
decreased eosinophil counts, ECp, histamine, tryptase
and albumin levels in nasal lavage fluid. Our findings
suggest that TXA2 plays an important role in the
pathogenesis of allergic rhinitis.
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